Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


IPO Report: Intrexon (XON)

By  +Follow August 7, 2013 11:03AM
Tickers Mentioned:

Nine other IPOs were scheduled for the week of August 5. The full IPO calendar can be found at IPOpremium.

Intrexon ($XON) is based in Germantown, MD.  XON scheduled a $124 million IPO with a market capitalization of $1.4 billion at a price range mid-point of $15, for Thursday, August 8, 2013.

The price range was set in theS-1 filed July 29, 2013.  The manager and joint manager are J.P. Morgan & Barclays.  The co-managers are Griffin Securities & Mizuho Securities


XON believes it is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems.

Q1 '13 $4 million in revenue with a $36 million loss.

One person owns 71%, apparently no venture capitalists, and no collaborators are investors. No patents, yet.

XON is bringing its technology to the market through collaborations, of which there are currently nine. Two are private companies and seven are public. The only large collaborator is Elanco, the animal health division of Eli Lilly and Company (LLY) , $57 billion market capitalization.

The rest are mostly micro cap companies, two of which have contributed stock to XON in return for the technology.

XON has an accumulated deficit of $363 million, and has raised $559 million to-date. Not entirely clear where that $559 million came from.


Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

% offered

annualizing Q1 '13

Cap (mm)





in IPO

Intrexon ($XON)








Only 9% is being offered on the IPO, a surprisingly small amount for a company that lost $36 million in Q1 '13. XON is IPO'ing at 4.3 times book, which seems reasonable


The rating is buy because if the technology is for real then XON could be a big stock. $559 million has been invested in the past several years, which is an indication some investors have done their due diligence, and 4.3 times book value is in range for this kind of company.

To put the conclusions and observations in context, the following is reorganized, edited, and summarized from the full S-1 referenced above:


XON believes it is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems.

Synthetic biology aims to engineer gene-based programs or codes to modify cellular function to achieve a desired biological outcome. For example, applications may include the replacement of a defective protein with a functional protein to treat a broad range of human and animal disease states, or the production of multiple proteins through the regulation of several genes in a cell to produce petrochemicals.

Using proprietary and complementary technologies, XON designs, builds and regulates gene programs, which are DNA sequences that consist of key genetic components.

A single gene program or a complex, multi-genic program are fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information.

DNA vectors can, in turn, be introduced into cells in order to generate a simple or complex cellular system, which are the basic and complex cellular activities that take place within a cell and the interaction of those systems in the greater cellular environment.

It is these genetically modified cell systems that can be used to produce proteins, produce small molecules, or serve as cell-based products, which enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences.

Intrexon's synthetic biology capabilities include the ability to precisely control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Exclusive Channel Collaborations (ECCs)

XON provides expertise in the engineering, creation and modification of gene programs and cellular systems, and collaborators are responsible for providing market and product development expertise, as well as regulatory, sales and marketing capabilities.

Generally, the collaborators compensate XON through payment of technology access fees, royalties, milestones and reimbursement of certain costs.

Nine ECC agreements

XON began entering into ECCs in 2011 and are currently party to nine such agreements.

Under these ECCs, XON is developing products in the fields of healthcare and food. In healthcare, ECCs include programs in oncology, anti-infectives, antibiotics and tissue repair.

In food, XON is working to increase the productivity and nutritional value of salmon and other fish. XON is are also working to establish ECCs in the areas of energy and environmental sciences.

Seven ECC companies are public

Except for Elanco (Eli Lilly division) the companies are all micro caps. The largest market cap is ZIOP, with a market cap of $249 million.

If the technology is to be worth $1.4 billion XON's IPO, then XON should have larger, better known collaborators receiving exclusives.


Effective January 6, 2011, XON entered into an ECC with ZIOPHARM Oncology, Inc. (ZIOP) , or ZIOPHARM, $249 million market capitalization.


Effective November 28, 2011, XON entered into an ECC with Elanco, the animal health division of Eli Lilly and Company (LLY) , $57 billion market capitalization.


Effective October 5, 2012, we entered into an ECC with Fibrocell Science, Inc. (FCSC) , $130 market capitalization.


Effective June 5, 2012, XON entered into an ECC with Oragenics, Inc. (OGEN) , $86 million market capitalization.

Synthetic Biologics

Effective August 6, 2012, XON entered into an ECC with Synthetic Biologics, Inc. (SYN) , $68 million market cap.


AquaBounty Technologies, Inc. ($ABTX), $45 million market cap. XON also owns 54% of ABTX, as of Mach 15, 2013.


Effective March 29, 2013, XON entered into an ECC with AmpliPhi BioSciences Corp. (APHB) , $11 million market cap. XON received 24 million shares as an upfront access fee.


Effective April 27, 2013, XON entered into an ECC with Soligenix, Inc. ($SNGX), $20 million market cap. XON received 1 million shares as an upfront technology access fee.

XON also entered into agreements with two private companies


Synthetic biology has applicability across many diverse end markets.


  Therapeutics. Both in human health and animal health, synthetic biology has the potential to enable the development of highly complex biological molecules as well as the ability to regulate complex biological processes, with advantages as compared to traditional therapeutics, both in vivo and ex vivo. It may be possible, for example, to create highly targeted precision therapeutics with few off-target or adverse effects.

  Bioproduction Synthetic biology allows new biologically based manufacturing techniques that have the potential to significantly lower the cost of goods for highly complex biological molecules, including both existing and novel biopharmaceuticals as well as small molecules.

  Diagnostics By utilizing the sensing and reporting capabilities of cells and specific cellular mechanisms, it may be possible to create highly sensitive diagnostics, to report on a patient's health and provide advance warning of changes in the state of the patient's health.


  Food animals By applying its suite of technologies, XON believes it can more rapidly develop livestock with commercially valuable attributes such as enhanced nutritional content, resistance to disease and increased growth efficiency.

  Agriculture XON believes that it can use gene expression and gene regulation technologies to provide highly complex traits related to enhanced nutritional content, product quality and disease resistance.

Energy and chemicals

  Energy XON has already achieved as proof of concept the conversion by engineered bacteria of methane to isobutanol, which is an alternative alcohol-based fuel.

  Chemicals Economically viable alternatives to carbon feed stocks are critical to the future and sustainability of the chemical industry.

Environmental sciences

  Biosensors The biosensor global market is forecasted to exceed $12 billion by 2016 and opportunities exist to capture a portion of this market through design and construction of unique biosensors that leverage XON's suite of proprietary and complementary technologies.

  Bioremediation The global market for microbial and associated bioremediation products is forecasted to reach over $1 billion by 2016. Industrial sources of soil and groundwater contamination present major environmental, policy and health issues because of the adverse effects of contaminants on humans and ecosystems. Bioremediation, which XON believes its technologies have the potential to enable, can provide an environmentally friendly, socially acceptable, effective and economically viable solution.

  Specialty Processes XON believes its suite of proprietary and complementary technologies has the potential to be used to introduce effective solutions for applications such as activated microbial filtration, waterborne pathogen elimination, and de-nitrification of waste and surface water.

XON's approch

The essence of XON's approach is to apply synthetic biology by using an iterative process that is rapid, automated and highly reproducible, in which we:

Design genes of interest and gene programs utilizing knowledge of cellular pathways and protein function;

Build biological molecules, gene programs and their variants to optimize performance of the biological system;

Test gene programs by inserting them into cellular systems and comparing the result(s) to the intended effects; and

Learn by utilizing information gained in our iterative processes to create better DNA vectors and gene programs using a more informed and efficient process to achieve improved outcomes.

As a result of its approach, XON has developed extensive knowledge about many classes of DNA components and the rules governing their expression and activity. XON has also assembled an inventory of these DNA components that XON can use to rationally construct unique vectors rapidly and with predictable outcomes. The knowledge embedded in XON's DNA database allows XON to create single gene and highly complex multigenic gene programs (an individual gene program containing multiple genes).

Integrated technologies

To support the design-build-test-learn approach, XON developed a unique suite of technologies. These technologies are complementary in nature and share the following key characteristics:

Platform neutral - outcome oriented.

Knowledge driven.

Rationally designed. XON's knowledge of biological systems and components allows XON to design, build and select gene programs and predict the probable outcome of these programs.

Capable of complexity. XON's technologies enable the design and precise control of complex biological molecules and multigenic gene programs.

Industrial scale. XON uses engineering principles and automation to enable products based on synthetic biology that are commercially viable.

Intellectual property

XON seeks patent protection for its platform technologies.


XON does not believe that it has any direct competitors who provide similar technologies which fully enable the commercialization of products developed using synthetic biology across a broad spectrum of biologically based industries. As a result, XON believes its competition is more indirect and general in nature, and falls into three broad categories:

• Synthetic biology service providers
There are companies that have competing technologies for individual pieces of XONs suite of complementary technologies. XON believes the following companies engage in the manufacture of DNA componentry: DNA 2.0, Inc., Blue Heron Biotech, LLC and Life Technologies Corporation. Another portion of our proprietary technology includes development of fully human monoclonal antibodies.

XON's technology utilizes advanced methods of stimulating antibody production in naïve human B-cells in vitro and specifically selecting those cells which produce antibodies that can bind a desired target, such as human toxins, tumor cells or microbial pathogens.

XON believes the following companies engage in the manufacture of human or human-like monoclonal antibodies: AbD SeroTec (a Bio-Rad Laboratories, Inc. company), Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Société Des Systèmes Biologiques, or BIOTEM, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc., AIIM Therapeutics and Open Monoclonal Technology, Inc.

• Industrial companies who may develop their own approach to synthetic biology. Large biopharmaceutical companies, energy companies, and ag-bio companies may pursue a proprietary synthetic biology strategy.

• Industrial companies who may develop competing products using other technologies. Large biopharmaceutical companies pursue other technologies for drug development, and large ag-bio companies pursue other technologies for the development of genetically modified crops.

5% stockholder pre-IPO

Randal J. Kirk, 71%

Use of proceeds

XON expects to net $113.5 million from its IPO.

Proceeds are allocated to further business development efforts to consummate new collaboration agreements with new companies across various commercial divisions, and for working capital and other general corporate purposes.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for XON
18 Sep 14 14:57:19
Intrexon Corporation (XON) is Up 37.82% in Volume http://t.co/uu4IyrnzAw $XON #invest #stocks #investing
18 Sep 14 14:21:19
@bradloncar I am ok with that but why Sanofi is partnering with $XON, they are also crazy ?
18 Sep 14 14:20:06
RT @bradloncar: Intrexon was the fourth leading gainer on the NYSE today. I said it yesterday, watch closely b/c it's a proxy for silliness…
Brad Loncar
18 Sep 14 14:11:38
Intrexon was the fourth leading gainer on the NYSE today. I said it yesterday, watch closely b/c it's a proxy for silliness. $XON
18 Sep 14 13:08:14
REBOUND CANDIDATES [ As Per VIDEO http://t.co/nYzIoDOEwT ]: $ANIP $BERY $JRJC $XON $XXII http://t.co/PzIBgb197q
Me Likeitalot
18 Sep 14 12:32:06
$ZIOP $XON Bizarro! Intrexon flying up, while Ziopharm taken down ~ this the takedown shakeout before the takeover of ZIOP by big pharma?
Alex Galan
18 Sep 14 12:09:38
$XON like this today
Me Likeitalot
18 Sep 14 10:30:37
@809trader $ZIOP $XON Yep, Intrexon not usually leave its little brother behind, so this low price is most unusual for this long.
18 Sep 14 10:07:50
@Melikeitalot agree $ziop always follow $xon moves, normally a day later
Me Likeitalot
18 Sep 14 10:01:15
$XON $ZIOP Nice move up lately on Intrexon ~ about time for Ziopharm (50/50 oncology partner) to begin its immense climb as well - buy now!
18 Sep 14 09:12:03
RT @Taarriqq: $twtr bounce again, $xon held for days, now nice bounce last two days, we posted abt it days ago, 2 min part of video http://…
18 Sep 14 08:58:33
$twtr bounce again, $xon held for days, now nice bounce last two days, we posted abt it days ago, 2 min part of video http://t.co/mlAKPhbqnb
Alex Galan
18 Sep 14 07:22:43
$XON should be 21.0 today
TV_Trading Ideas
17 Sep 14 14:52:42
XON possible breakout to watch $XON http://t.co/GvMoFgkLk5
Brad Loncar
17 Sep 14 14:05:01
You know risk is on when $XON starts showing up on the top gainers list.
biotech 2050
17 Sep 14 09:32:15
Unbelievable amount of mega yachts today at Vittoriosa Yacht Marina Malta $CELG $GILD $TGTX $ZIOP $NPSP $XON $HALO http://t.co/kOjxS0uV9q
17 Sep 14 09:30:01
Fibrocell Science : Hosting R&D Day on September 24, 2014 http://t.co/wid7F9MlWg $FCSC $XON
17 Sep 14 08:44:06
RT @OMillionaires: Watch this $128.58 break on $SSYS - will see $130+ very quickly $DDD $XON$ $VJET $PRLB
Memphisto Pheles
17 Sep 14 08:27:51
RT @OMillionaires: Watch this $128.58 break on $SSYS - will see $130+ very quickly $DDD $XON$ $VJET $PRLB
Option Millionaires
17 Sep 14 08:16:04
Watch this $128.58 break on $SSYS - will see $130+ very quickly $DDD $XON$ $VJET $PRLB
17 Sep 14 07:30:49
This could gap $XON http://t.co/Hj7zfhAghX
Day Trade Alerts
17 Sep 14 07:19:18
via #AlertTrade Price Action Alert $XON - INTREXON CORP #stocks #intraday http://t.co/VS8RO1bzXJ
17 Sep 14 04:15:52
$SNGX $XON Soligenix Reports FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
17 Sep 14 04:05:06
Intrexon : Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lym... http://t.co/7IhTntFqoN $XON
16 Sep 14 16:27:35
$XON Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog http://t.co/XVnRHBv9ik
Stock Signaling
16 Sep 14 16:01:07
After Hours Price Advances: $MDT $AGIO $GST $AKS $STLD $GTAT $SD $SODA $ACRX $XON $YRCW $SLXP $ENDP $SNTA $IBB http://t.co/Vtx6dLy0Nw #dow
16 Sep 14 04:18:22
Bullish MACD Crossovers 2/2 $HIBB $I $IGT $LGF $LIQT $LRN $LTS $ORI $PER $PNR $REXX $RLYP $XON http://t.co/1kBrNArHBR
15 Sep 14 21:49:31
RT @BiotechMoney18: $ZIOP trading @ multiples support level at $3. P2 breast cancer by yr end maybe like $PBYI ? also melanoma data. Randal…
biotech 2050
15 Sep 14 11:46:33
RT @BiotechMoney18: $ZIOP trading @ multiples support level at $3. P2 breast cancer by yr end maybe like $PBYI ? also melanoma data. Randal…
Me Likeitalot
15 Sep 14 11:43:56
RT @BiotechMoney18: $ZIOP trading @ multiples support level at $3. P2 breast cancer by yr end maybe like $PBYI ? also melanoma data. Randal…
$$$ Money $$$
15 Sep 14 11:42:15
$ZIOP trading @ multiples support level at $3. P2 breast cancer by yr end maybe like $PBYI ? also melanoma data. Randal Kirk play like $XON
biotech 2050
15 Sep 14 09:51:36
@fezziwig2008 total manipulation and to the list you can add on $GILD $CELG $ZIOP $DYAX $PTX $CRMD $XON and last but not least $NPSP
biotech 2050
15 Sep 14 07:08:25
Longs: - share buybacks at a lower price - weak hands out - new long holders in $CELG $GILD $HALO $NPSP $DYAX $ZIOP $PTX $TGTX $XON $CRMD
biotech 2050
14 Sep 14 22:48:02
Third Security holdings include: $XON 62.5M $HALO 19.8M $ZIOP 17.8M $XON committed to buy add. $19M shares of $ZIOP http://t.co/4Mj4DqV5w8
Auto Binary option
12 Sep 14 10:35:46
RT @ForTraders: Intrexon : Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (P... http://t.co/…
The Fly
12 Sep 14 10:30:55
$SYN $XON Synthetic Biologics confirms receipt of orphan drug designation for SYN-005: Full Story http://t.co/gjWCo3sZqI
12 Sep 14 10:30:02
Intrexon : Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (P... http://t.co/qMfTGQTpGv $XON
Ticker Report
12 Sep 14 04:31:41
Intrexon Corp Research Coverage Started at TheStreet $XON http://t.co/fKTkDR6IJn
12 Sep 14 04:10:12
Intrexon : Assigned Patent http://t.co/2FjfAF4JvY $XON
11 Sep 14 11:07:36
RT @Taarriqq: $GPRO expected a pull bak 2day as posted last night $TWTR 45-52$ move since last video $AAPL $FB $QQQ $XON $POT http://t.c…
11 Sep 14 11:03:59
$GPRO expected a pull bak 2day as posted last night $TWTR 45-52$ move since last video $AAPL $FB $QQQ $XON $POT http://t.co/xdrR4PReyA
Daily Contracts
11 Sep 14 09:34:01
Real-Time feed of company contracts, original agreements and executive updates from Intrexon Corp $XON http://t.co/g1aFcFmig0
Alexander Morris
11 Sep 14 09:17:19
$XON: Exc 1DyHIGH=18.55, hits:1, ch:+0.2%, PrvCHi+, 2:1Accel+, tf:3f, FirmTrnd-:+50%, LowFlt[15.0M], HiPctSht[65%:19d], PrvClGap-[-1.3%]
11 Sep 14 06:48:55
Short Squeeze Alerts $DNDN $RSH $TFM $XON $USU $ARIA $CNVR $AFSI $RPTP http://t.co/vRTWxV5Spu
biotech 2050
10 Sep 14 21:53:56
Thanks biotech shorts for cheap shares to long holders +removing all weak holders $CELG $NPSP $HALO $ZIOP $TGTX $XON $PTX $GILD $DYAX $CRMD
By  +Follow August 7, 2013 11:03AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.